Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial

Neefs, Jolien
van den Berg, Nicoline W. E.
Krul, S. bastien P. J.
Boekholdt, S. Matthijs
de Groot, Joris R.

February 2020

Background: Mineralocorticoid receptor antagonists (MRAs) reduce the risk of atrial fibrillation (AF...

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

Butler, Javed
Anstrom, Kevin J.
Felker, G. Michael
Givertz, Michael M.
Kalogeropoulos, Andreas P
Konstam, Marvin A.
Mann, Douglas L.
Margulies, Kenneth B.
McNulty, Steven E
Mentz, Robert J.
Redfield, Margaret M.
Tang, W.H. Wilson
Whellan, David J.
Shah, Monica
Desvigne-Nickens, Patrice
Hernandez, Adrian F.
Braunwald, Eugene

September 2017

Importance: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mi...

Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)

Maisel, Alan
Xue, Yang
van Veldhuisen, Dirk J.
Voors, Adriaan A.
Jaarsma, Tiny
Pang, Peter S.
Butler, Javed
Pitt, Bertram
Clopton, Paul
de Boer, Rudolf A.

September 2014

The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients w...

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk

Jun-Feng Li
Xiang Qu
Zhan Gao
Chang-Xi Chen
Feng-Yu Zhang
Ling Cheng
Xi Zhou
Hao Zhou

January 2023

Aims: Few studies have compared the association between dosing of spironolactone and outcomes in pat...

Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function

Beldhuis, Iris E.
Myhre, Peder L.
Bristow, Michael
Claggett, Brian
Damman, Kevin
Fang, James C.
Fleg, Jerome L.
McKinlay, Sonja
Lewis, Eldrin F.
O'Meara, Eileen
Pitt, Bertram
Shah, Sanjiv J.
Vardeny, Orly
Voors, Adriaan A.
Pfeffer, Marc A.
Solomon, Scott D.
Desai, Akshay S.

March 2021

BACKGROUND Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone i...

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease

Beldhuis, Iris E
Myhre, Peder L
Claggett, Brian
Damman, Kevin
Fang, James C
Lewis, Eldrin F
O'Meara, Eileen
Pitt, Bertram
Shah, Sanjiv J
Voors, Adriaan A
Pfeffer, Marc A
Solomon, Scott D
Desai, Akshay S

January 2019

OBJECTIVES: This study investigated the association between baseline renal function and the net bene...

Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials

Ferreira, João Pedro
Cleland, John G.
Girerd, Nicolas
Bozec, Erwan
Rossignol, Patrick
Pellicori, Pierpaolo
Cosmi, Franco
Mariottoni, Beatrice
Solomon, Scott D.
Pitt, Bertram
Pfeffer, Marc A.
Shah, Amil M.
Petutschnigg, Johannes
Pieske, Burkert
Edelmann, Frank
Zannad, Faiez

October 2022

Background: Spironolactone is currently used in a large proportion of patients with heart failure ...

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction

Mark N. Belkin
John E. Blair
Sanjiv J. Shah
Francis J. Alenghat

October 2021

Abstract Aims The TOPCAT trial showed no benefit for spironolactone in heart failure patients with p...

The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study

강석민
이혜선

February 2022

Background: Randomized clinical trials of spironolactone showed significant mortality reduction in p...

Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

Lewis, Eldrin
Kim, Hae-Young
Claggett, Brian
Spertus, John
Heitner, John F
Assmann, Susan F
Kenwood, Christopher T
Solomon, Scott D
Desai, Akshay S
Fang, James C
McKinlay, Sonia A
Pitt, Bertram A
Pfeffer, Marc A

March 2016

BACKGROUND: Heart failure (HF) with preserved ejection fraction patients have equally impaired healt...

Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction

Bayoumi, Essraa
Lam, Phillip H
Dooley, Daniel J
Singh, Steven
Faselis, Charles
Morgan, Charity J
Patel, Samir
Sheriff, Helen M
Mohammed, Selma F
Palant, Carlos E
Pitt, Bertram
Fonarow, Gregg C
Ahmed, Ali

January 2019

BackgroundThe efficacy of mineralocorticoid receptor antagonists or aldosterone antagonists in heart...

Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction

Yan-guo Xin (5721731)
Xin Chen (14149)
Yi-nan Zhao (5721734)
Jian Hu (31535)
Yingxian Sun (339676)
Wen-yu Hu (5721737)

September 2018

Aim: The treatment effects of spironolactone on heart failure with reduced (HFrEF LVEF Method: This...

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Pitt, B.
Zannad, F.
Remme, W.J.
Cody, R.
Castaigne, A.
Perez, A.
Palensky, J.
Wittes, J.

January 1999

BACKGROUND AND METHODS: Aldosterone is important in the pathophysiology of heart failure. In a doubl...

(RS27) Evaluation of Spironolactone Use and the Effects on Left Ventricle Ejection Fraction Among Chronic Heart Failure Patients in Hospital Kuala Lumpur: A Retrospective Observational Cohort Study.

Jivanraj R Nagarajah

March 2022

Introduction: Spironolactone has been indicated in managing patients with heart failure with reduce...

Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry

송미경
오재원
윤종찬
홍남기
강석민

January 2015

BACKGROUNDS: We investigated the relationship between spironolactone use and all-cause mortality in ...

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial

Neefs, Jolien
van den Berg, Nicoline W. E.
Krul, S. bastien P. J.
Boekholdt, S. Matthijs
de Groot, Joris R.

February 2020

Background: Mineralocorticoid receptor antagonists (MRAs) reduce the risk of atrial fibrillation (AF...

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

Butler, Javed
Anstrom, Kevin J.
Felker, G. Michael
Givertz, Michael M.
Kalogeropoulos, Andreas P
Konstam, Marvin A.
Mann, Douglas L.
Margulies, Kenneth B.
McNulty, Steven E
Mentz, Robert J.
Redfield, Margaret M.
Tang, W.H. Wilson
Whellan, David J.
Shah, Monica
Desvigne-Nickens, Patrice
Hernandez, Adrian F.
Braunwald, Eugene

September 2017

Importance: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mi...

Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)

Maisel, Alan
Xue, Yang
van Veldhuisen, Dirk J.
Voors, Adriaan A.
Jaarsma, Tiny
Pang, Peter S.
Butler, Javed
Pitt, Bertram
Clopton, Paul
de Boer, Rudolf A.

September 2014

The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients w...

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk

Jun-Feng Li
Xiang Qu
Zhan Gao
Chang-Xi Chen
Feng-Yu Zhang
Ling Cheng
Xi Zhou
Hao Zhou

January 2023

Aims: Few studies have compared the association between dosing of spironolactone and outcomes in pat...

Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function

Beldhuis, Iris E.
Myhre, Peder L.
Bristow, Michael
Claggett, Brian
Damman, Kevin
Fang, James C.
Fleg, Jerome L.
McKinlay, Sonja
Lewis, Eldrin F.
O'Meara, Eileen
Pitt, Bertram
Shah, Sanjiv J.
Vardeny, Orly
Voors, Adriaan A.
Pfeffer, Marc A.
Solomon, Scott D.
Desai, Akshay S.

March 2021

BACKGROUND Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone i...

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease

Beldhuis, Iris E
Myhre, Peder L
Claggett, Brian
Damman, Kevin
Fang, James C
Lewis, Eldrin F
O'Meara, Eileen
Pitt, Bertram
Shah, Sanjiv J
Voors, Adriaan A
Pfeffer, Marc A
Solomon, Scott D
Desai, Akshay S

January 2019

OBJECTIVES: This study investigated the association between baseline renal function and the net bene...

Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials

Ferreira, João Pedro
Cleland, John G.
Girerd, Nicolas
Bozec, Erwan
Rossignol, Patrick
Pellicori, Pierpaolo
Cosmi, Franco
Mariottoni, Beatrice
Solomon, Scott D.
Pitt, Bertram
Pfeffer, Marc A.
Shah, Amil M.
Petutschnigg, Johannes
Pieske, Burkert
Edelmann, Frank
Zannad, Faiez

October 2022

Background: Spironolactone is currently used in a large proportion of patients with heart failure ...

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction

Mark N. Belkin
John E. Blair
Sanjiv J. Shah
Francis J. Alenghat

October 2021

Abstract Aims The TOPCAT trial showed no benefit for spironolactone in heart failure patients with p...

The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study

강석민
이혜선

February 2022

Background: Randomized clinical trials of spironolactone showed significant mortality reduction in p...

Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

Lewis, Eldrin
Kim, Hae-Young
Claggett, Brian
Spertus, John
Heitner, John F
Assmann, Susan F
Kenwood, Christopher T
Solomon, Scott D
Desai, Akshay S
Fang, James C
McKinlay, Sonia A
Pitt, Bertram A
Pfeffer, Marc A

March 2016

BACKGROUND: Heart failure (HF) with preserved ejection fraction patients have equally impaired healt...

Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction

Bayoumi, Essraa
Lam, Phillip H
Dooley, Daniel J
Singh, Steven
Faselis, Charles
Morgan, Charity J
Patel, Samir
Sheriff, Helen M
Mohammed, Selma F
Palant, Carlos E
Pitt, Bertram
Fonarow, Gregg C
Ahmed, Ali

January 2019

BackgroundThe efficacy of mineralocorticoid receptor antagonists or aldosterone antagonists in heart...

Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction

Yan-guo Xin (5721731)
Xin Chen (14149)
Yi-nan Zhao (5721734)
Jian Hu (31535)
Yingxian Sun (339676)
Wen-yu Hu (5721737)

September 2018

Aim: The treatment effects of spironolactone on heart failure with reduced (HFrEF LVEF Method: This...

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Pitt, B.
Zannad, F.
Remme, W.J.
Cody, R.
Castaigne, A.
Perez, A.
Palensky, J.
Wittes, J.

January 1999

BACKGROUND AND METHODS: Aldosterone is important in the pathophysiology of heart failure. In a doubl...

(RS27) Evaluation of Spironolactone Use and the Effects on Left Ventricle Ejection Fraction Among Chronic Heart Failure Patients in Hospital Kuala Lumpur: A Retrospective Observational Cohort Study.

Jivanraj R Nagarajah

March 2022

Introduction: Spironolactone has been indicated in managing patients with heart failure with reduce...

Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry

송미경
오재원
윤종찬
홍남기
강석민

January 2015

BACKGROUNDS: We investigated the relationship between spironolactone use and all-cause mortality in ...

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial

Neefs, Jolien
van den Berg, Nicoline W. E.
Krul, S. bastien P. J.
Boekholdt, S. Matthijs
de Groot, Joris R.

February 2020

Background: Mineralocorticoid receptor antagonists (MRAs) reduce the risk of atrial fibrillation (AF...

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

Butler, Javed
Anstrom, Kevin J.
Felker, G. Michael
Givertz, Michael M.
Kalogeropoulos, Andreas P
Konstam, Marvin A.
Mann, Douglas L.
Margulies, Kenneth B.
McNulty, Steven E
Mentz, Robert J.
Redfield, Margaret M.
Tang, W.H. Wilson
Whellan, David J.
Shah, Monica
Desvigne-Nickens, Patrice
Hernandez, Adrian F.
Braunwald, Eugene

September 2017

Importance: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mi...

Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)

Maisel, Alan
Xue, Yang
van Veldhuisen, Dirk J.
Voors, Adriaan A.
Jaarsma, Tiny
Pang, Peter S.
Butler, Javed
Pitt, Bertram
Clopton, Paul
de Boer, Rudolf A.

September 2014

The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients w...

Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT

Abstract

Extracted data

Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT

Abstract

Extracted data

Related items

Related items